Antidiabetic Drugs for Steatotic Liver Disease
Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes
Sponsor: Yonsei University
Listed as NCT03646292, this PHASE4 trial focuses on Digestive System Disease and Empagliflozin and remains completed. Sponsored by Yonsei University, it has been updated 13 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE4
-
Jan 2025 — Apr 2025 [monthly]
Completed PHASE4
-
Dec 2024 — Jan 2025 [monthly]
Completed PHASE4
-
Oct 2024 — Dec 2024 [monthly]
Completed PHASE4
Status: Unknown → Completed
▶ Show 8 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Mar 2019 — Nov 2020 [monthly]
Not Yet Recruiting PHASE4
-
Feb 2019 — Mar 2019 [monthly]
Not Yet Recruiting PHASE4
-
Sep 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Yonsei University
For direct contact, visit the study record on ClinicalTrials.gov .